<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Crb Token Health, SL</title>
	<atom:link href="https://crbtokenhealth.com/en/feed/" rel="self" type="application/rss+xml" />
	<link>https://crbtokenhealth.com/en/crb-token-health-i/</link>
	<description>SPV de tokenización de activos</description>
	<lastBuildDate>Thu, 17 Oct 2024 11:31:49 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://crbtokenhealth.com/wp-content/uploads/2024/04/cropped-CRB_TOKEN_HEALTH_logo-32x32.jpg</url>
	<title>Crb Token Health, SL</title>
	<link>https://crbtokenhealth.com/en/crb-token-health-i/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Alzheimer: When Early Diagnosis Makes a Difference</title>
		<link>https://crbtokenhealth.com/en/alzheimer-when-early-diagnosis-makes-a-difference/</link>
					<comments>https://crbtokenhealth.com/en/alzheimer-when-early-diagnosis-makes-a-difference/#respond</comments>
		
		<dc:creator><![CDATA[CrbTokenHealth]]></dc:creator>
		<pubDate>Tue, 24 Sep 2024 11:08:25 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://crbtokenhealth.com/?p=1230</guid>

					<description><![CDATA[<p>Alzheimer&#8217;s is a neurodegenerative disease that primarily affects older adults and is associated with the aging population. As societies age, the number of dementia cases, particularly Alzheimer&#8217;s, increases. However, some developed countries have seen a decline in the incidence of the disease due to improvements in education, sanitation, and lifestyle. Despite these advancements, Alzheimer&#8217;s remains [&#8230;]</p>
<p>La entrada <a href="https://crbtokenhealth.com/en/alzheimer-when-early-diagnosis-makes-a-difference/">Alzheimer: When Early Diagnosis Makes a Difference</a> se publicó primero en <a href="https://crbtokenhealth.com/en/crb-token-health-i">Crb Token Health, SL</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="flex max-w-full flex-col flex-grow">
<div class="min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words [.text-message+&amp;]:mt-5" dir="auto" data-message-author-role="assistant" data-message-id="09efc4e8-c1f0-4e9d-8cba-0a9352b657a5" data-message-model-slug="gpt-4o">
<div class="flex w-full flex-col gap-1 empty:hidden first:pt-[3px]">
<div class="markdown prose w-full break-words dark:prose-invert light">
<div>
<div>Alzheimer&#8217;s is a neurodegenerative disease that primarily affects older adults and is associated with the aging population. As societies age, the number of dementia cases, particularly Alzheimer&#8217;s, increases. However, some developed countries have seen a decline in the incidence of the disease due to improvements in education, sanitation, and lifestyle.</div>
<div>Despite these advancements, Alzheimer&#8217;s remains a significant challenge for the scientific community and healthcare systems due to the complexity of its causes and the lack of effective treatments. Currently, more than 50 million people worldwide are affected, and this number is projected to exceed 100 million by 2050.</div>
<div>The most widely accepted theory regarding the origin of Alzheimer&#8217;s is the &#8220;amyloid cascade,&#8221; which suggests that beta-amyloid, a protein fragment, accumulates in the brain, causing neuronal death and the malfunction of certain brain regions. Although anti-amyloid treatments have been developed to combat this buildup, the results have been modest, and the treatments come with serious side effects, which is why they have not yet been approved in the European Union.</div>
<div>For a definitive diagnosis of Alzheimer&#8217;s, proper clinical evaluation and the detection of specific biomarkers, such as beta-amyloid and tau protein, are recommended through PET-amyloid imaging tests or lumbar punctures. These procedures are costly, have limited availability, and can be invasive.</div>
<div>Research is ongoing, and experts are optimistic about the development of new approaches, such as blood biomarkers, which are already being implemented in some centers. Age is one of the main risk factors for developing Alzheimer&#8217;s, with a significant increase in risk after the age of 65 and a prevalence of 27% among those over 90. Other non-modifiable factors include genetic predisposition.</div>
<div></div>
<div>Published by <a href="https://www.elplural.com/sociedad/alzheimer-cuando-diagnostico-temprano-marca-diferencia_337387102">Elplural.com</a></div>
</div>
</div>
</div>
</div>
</div>
<p>La entrada <a href="https://crbtokenhealth.com/en/alzheimer-when-early-diagnosis-makes-a-difference/">Alzheimer: When Early Diagnosis Makes a Difference</a> se publicó primero en <a href="https://crbtokenhealth.com/en/crb-token-health-i">Crb Token Health, SL</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://crbtokenhealth.com/en/alzheimer-when-early-diagnosis-makes-a-difference/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>&#8220;The CREA participates in an investigation to evaluate a new Alzheimer&#8217;s screening method.&#8221;</title>
		<link>https://crbtokenhealth.com/en/the-crea-participates-in-an-investigation-to-evaluate-a-new-alzheimers-screening-method/</link>
					<comments>https://crbtokenhealth.com/en/the-crea-participates-in-an-investigation-to-evaluate-a-new-alzheimers-screening-method/#respond</comments>
		
		<dc:creator><![CDATA[CrbTokenHealth]]></dc:creator>
		<pubDate>Mon, 24 Jun 2024 10:55:26 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://crbtokenhealth.com/?p=1196</guid>

					<description><![CDATA[<p>We are pleased to announce our participation in an innovative project featured in CREA. Below is the text of the publication: Biocross has initiated a study to evaluate the quantification of Apolipoprotein E4 (ApoE4) as a risk marker for Alzheimer&#8217;s disease, cardiovascular diseases, and type II diabetes mellitus. In this project, which involves collaboration between [&#8230;]</p>
<p>La entrada <a href="https://crbtokenhealth.com/en/the-crea-participates-in-an-investigation-to-evaluate-a-new-alzheimers-screening-method/">&#8220;The CREA participates in an investigation to evaluate a new Alzheimer&#8217;s screening method.&#8221;</a> se publicó primero en <a href="https://crbtokenhealth.com/en/crb-token-health-i">Crb Token Health, SL</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>We are pleased to announce our participation in an innovative project featured in CREA. Below is the text of the publication:</p>
<p>Biocross has initiated a study to evaluate the quantification of Apolipoprotein E4 (ApoE4) as a risk marker for Alzheimer&#8217;s disease, cardiovascular diseases, and type II diabetes mellitus.</p>
<p>In this project, which involves collaboration between various Spanish and Mexican institutions, Biocross has provided the Imserso reference center with a turbidity analyzer laboratory equipment for the study&#8217;s development.</p>
<p>This research opens up the possibility of a simple and inexpensive screening method to adequately identify and stratify healthy individuals who are more susceptible to early-onset dementia.</p>
<p>&#8220;<a href="https://crealzheimer.imserso.es/detalle-actualidad/-/asset_publisher/IVpvoGMkHVB6/content/el-crea-participa-en-una-investigacion-para-evaluar-un-nuevo-metodo-de-cribado-de-alzheimer/20123">El <abbr title="Centro de Referencia Estatal del Alzheimer">CREA</abbr> participa en una investigación para evaluar un nuevo método de cribado de alzhéimer</a>&#8220;, <em>Imserso</em>, 20/6/2024.</p>
<p>La entrada <a href="https://crbtokenhealth.com/en/the-crea-participates-in-an-investigation-to-evaluate-a-new-alzheimers-screening-method/">&#8220;The CREA participates in an investigation to evaluate a new Alzheimer&#8217;s screening method.&#8221;</a> se publicó primero en <a href="https://crbtokenhealth.com/en/crb-token-health-i">Crb Token Health, SL</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://crbtokenhealth.com/en/the-crea-participates-in-an-investigation-to-evaluate-a-new-alzheimers-screening-method/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Pablo Cabello: &#8220;Reducing ApoE4 in Carriers is a Therapeutic Goal in Alzheimer&#8217;s Disease&#8221;</title>
		<link>https://crbtokenhealth.com/en/pablo-cabello-reducing-apoe4-in-carriers-is-a-therapeutic-goal-in-alzheimers-disease/</link>
					<comments>https://crbtokenhealth.com/en/pablo-cabello-reducing-apoe4-in-carriers-is-a-therapeutic-goal-in-alzheimers-disease/#respond</comments>
		
		<dc:creator><![CDATA[CrbTokenHealth]]></dc:creator>
		<pubDate>Fri, 24 May 2024 09:06:57 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://crbtokenhealth.com/?p=1145</guid>

					<description><![CDATA[<p>Dr. Pablo Cabello Albendea, from the Hospital Ramón y Cajal, emphasizes the importance of reducing the levels of the APOE4 protein in carriers to treat Alzheimer&#8217;s disease. A recent study by the “National Institute of Aging” suggests that reducing APOE4 can be therapeutic and that it is crucial to identify and quantify this protein to [&#8230;]</p>
<p>La entrada <a href="https://crbtokenhealth.com/en/pablo-cabello-reducing-apoe4-in-carriers-is-a-therapeutic-goal-in-alzheimers-disease/">Pablo Cabello: &#8220;Reducing ApoE4 in Carriers is a Therapeutic Goal in Alzheimer&#8217;s Disease&#8221;</a> se publicó primero en <a href="https://crbtokenhealth.com/en/crb-token-health-i">Crb Token Health, SL</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Dr. Pablo Cabello Albendea, from the Hospital Ramón y Cajal, emphasizes the importance of reducing the levels of the APOE4 protein in carriers to treat Alzheimer&#8217;s disease. A recent study by the “National Institute of Aging” suggests that reducing APOE4 can be therapeutic and that it is crucial to identify and quantify this protein to personalize treatments. Additionally, new gene therapies and strategies combined with anti-amyloid treatments are being explored. Research needs to address when and how to apply these therapies effectively, considering ethnic differences in APOE4 expression.</p>
<p><strong>Published in:</strong></p>
<ul>
<li>Educa-med: <span style="color: #1db4c1;"><a style="color: #1db4c1;" href="https://educa-med.online/pablo-cabello-reducir-apoe4-en-portadores-es-un-objetivo-terapeutico-en-la-enfermedad-de-alzheimer/">&#8220;Pablo Cabello: “Reducir ApoE4 en portadores es un objetivo terapéutico en la enfermedad de Alzheimer”<br />
</a></span></li>
</ul>
<p><span style="color: #1db4c1;"><a style="color: #1db4c1;" href="https://crbtokenhealth.com/">Crb Token Health, SL</a></span></p>
<p>La entrada <a href="https://crbtokenhealth.com/en/pablo-cabello-reducing-apoe4-in-carriers-is-a-therapeutic-goal-in-alzheimers-disease/">Pablo Cabello: &#8220;Reducing ApoE4 in Carriers is a Therapeutic Goal in Alzheimer&#8217;s Disease&#8221;</a> se publicó primero en <a href="https://crbtokenhealth.com/en/crb-token-health-i">Crb Token Health, SL</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://crbtokenhealth.com/en/pablo-cabello-reducing-apoe4-in-carriers-is-a-therapeutic-goal-in-alzheimers-disease/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Biocross: &#8220;A Simple Test Can Identify the Risk or Prognosis of Developing Alzheimer&#8217;s in the Futur</title>
		<link>https://crbtokenhealth.com/en/biocross-a-simple-test-can-identify-the-risk-or-prognosis-of-developing-alzheimers-in-the-futur/</link>
					<comments>https://crbtokenhealth.com/en/biocross-a-simple-test-can-identify-the-risk-or-prognosis-of-developing-alzheimers-in-the-futur/#respond</comments>
		
		<dc:creator><![CDATA[CrbTokenHealth]]></dc:creator>
		<pubDate>Thu, 16 May 2024 12:34:02 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://crbtokenhealth.com/?p=963</guid>

					<description><![CDATA[<p>The company Biocross has developed two innovative blood tests, e4Risk® and e4Quant®, which identify and quantify the presence of the APOE4 gene, related to various metabolic and neurodegenerative diseases such as type 2 diabetes, cardiovascular diseases, and Alzheimer’s. A recent study by the Research Institute of the Hospital de la Santa Creu i Sant Pau [&#8230;]</p>
<p>La entrada <a href="https://crbtokenhealth.com/en/biocross-a-simple-test-can-identify-the-risk-or-prognosis-of-developing-alzheimers-in-the-futur/">Biocross: &#8220;A Simple Test Can Identify the Risk or Prognosis of Developing Alzheimer&#8217;s in the Futur</a> se publicó primero en <a href="https://crbtokenhealth.com/en/crb-token-health-i">Crb Token Health, SL</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The company Biocross has developed two innovative blood tests, e4Risk® and e4Quant®, which identify and quantify the presence of the APOE4 gene, related to various metabolic and neurodegenerative diseases such as type 2 diabetes, cardiovascular diseases, and Alzheimer’s. A recent study by the Research Institute of the Hospital de la Santa Creu i Sant Pau in Barcelona revealed that almost all individuals with a duplication of the APOE4 gene develop biomarkers associated with dementia. These tests represent a significant advancement in the early identification and management of these diseases, offering new hope for improving the health and quality of life of those affected.</p>
<p>Published in: &#8220;<a href="https://educa-med.online/enrique-castellon-un-sencillo-test-puede-identificar-el-riesgo-o-pronostico-de-padecer-alzheimer-en-el-futuro/">Enrique Castellón: “Un sencillo test puede identificar el riesgo o pronóstico de padecer Alzheimer en el futuro”&#8221;</a>, <em>Educa-med.</em></p>
<p><span style="color: #1db4c1;"><a style="color: #1db4c1;" href="https://crbtokenhealth.com/">Crb Token Health, SL</a></span></p>
<p>La entrada <a href="https://crbtokenhealth.com/en/biocross-a-simple-test-can-identify-the-risk-or-prognosis-of-developing-alzheimers-in-the-futur/">Biocross: &#8220;A Simple Test Can Identify the Risk or Prognosis of Developing Alzheimer&#8217;s in the Futur</a> se publicó primero en <a href="https://crbtokenhealth.com/en/crb-token-health-i">Crb Token Health, SL</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://crbtokenhealth.com/en/biocross-a-simple-test-can-identify-the-risk-or-prognosis-of-developing-alzheimers-in-the-futur/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Apoe4: A new genetic cause of Alzheimer&#8217;s discovered that affects more than 2% of the population</title>
		<link>https://crbtokenhealth.com/en/apoe4-gene-a-new-genetic-cause-of-alzheimers-discovered-that-affects-more-than-2-of-the-population/</link>
					<comments>https://crbtokenhealth.com/en/apoe4-gene-a-new-genetic-cause-of-alzheimers-discovered-that-affects-more-than-2-of-the-population/#respond</comments>
		
		<dc:creator><![CDATA[CrbTokenHealth]]></dc:creator>
		<pubDate>Mon, 13 May 2024 15:35:04 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://crbtokenhealth.com/?p=915</guid>

					<description><![CDATA[<p>The Research Institute of the Hospital de la Santa Creu i Sant Pau in Barcelona has identified a new genetic form of Alzheimer&#8217;s: the duplication of the APOE4 gene. This discovery highlights the importance of the APOE4 gene in Alzheimer&#8217;s research. Biocross aims to position APOE4 as a reference biomarker for the risk/prognosis of diseases [&#8230;]</p>
<p>La entrada <a href="https://crbtokenhealth.com/en/apoe4-gene-a-new-genetic-cause-of-alzheimers-discovered-that-affects-more-than-2-of-the-population/">Apoe4: A new genetic cause of Alzheimer&#8217;s discovered that affects more than 2% of the population</a> se publicó primero en <a href="https://crbtokenhealth.com/en/crb-token-health-i">Crb Token Health, SL</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The Research Institute of the Hospital de la Santa Creu i Sant Pau in Barcelona has identified a new genetic form of Alzheimer&#8217;s: the duplication of the APOE4 gene. This discovery highlights the importance of the APOE4 gene in Alzheimer&#8217;s research.</p>
<p>Biocross aims to position APOE4 as a reference biomarker for the risk/prognosis of diseases related to alterations in lipid metabolism (Alzeimer&#8217;s, cardiovascular diseases, Diabetes Mellitus Type II, pathologies that grow above the population average) and to identify and quantify this biomarker through its tests: e4Risk and e4Quant.</p>
<p>This discovery reinforces the need for specific preventive strategies and opens new perspectives for more personalized therapies in the future. It is an important step forward in the understanding and treatment of Alzheimer&#8217;s, highlighting the importance of continued research in the field of neurodegenerative diseases.</p>
<p><strong>Published in the following media outlets:</strong></p>
<ul>
<li>El País: <span style="color: #1db4c1;"><a style="color: #1db4c1;" href="https://elpais.com/ciencia/2024-05-06/identificada-una-nueva-forma-de-alzheimer-genetico-presente-en-millones-de-personas.html">&#8220;Identificada una nueva forma de alzhéimer genético presente en millones de personas&#8221;</a></span>,  6 de mayo 2024.</li>
<li>La Vanguardia: <span style="color: #1db4c1;"><a style="color: #1db4c1;" href="https://www.lavanguardia.com/ciencia/20240506/9614687/descubierta-nueva-causa-genetica-alzheimer-afecta-millon-personas-espana.html">&#8220;Descubierta una nueva causa genética del alzheimer que afecta a un millón de personas en España&#8221;</a></span>, 6 de mayo 2024.</li>
<li>Onda Cero:<span style="color: #1db4c1;"> <a style="color: #1db4c1;" href="https://www.ondacero.es/noticias/salud/estudio-identifica-nueva-forma-genetica-alzheimer-que-afecta-mas-2-poblacion_202405066638f7508e66020001d17132.html">&#8220;Un estudio identifica una nueva forma genética del alzhéimer que afecta a más del 2% de la población&#8221;</a></span>, 6 de mayo 2024.</li>
</ul>
<p><span style="color: #1db4c1;"><a style="color: #1db4c1;" href="https://crbtokenhealth.com/">Crb Token Health, SL</a></span></p>
<p>La entrada <a href="https://crbtokenhealth.com/en/apoe4-gene-a-new-genetic-cause-of-alzheimers-discovered-that-affects-more-than-2-of-the-population/">Apoe4: A new genetic cause of Alzheimer&#8217;s discovered that affects more than 2% of the population</a> se publicó primero en <a href="https://crbtokenhealth.com/en/crb-token-health-i">Crb Token Health, SL</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://crbtokenhealth.com/en/apoe4-gene-a-new-genetic-cause-of-alzheimers-discovered-that-affects-more-than-2-of-the-population/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Summary Video of the Event: &#8220;Cerco al Alzheimer&#8221;</title>
		<link>https://crbtokenhealth.com/en/summary-video-of-the-event-cerco-al-alzheimer/</link>
					<comments>https://crbtokenhealth.com/en/summary-video-of-the-event-cerco-al-alzheimer/#respond</comments>
		
		<dc:creator><![CDATA[CrbTokenHealth]]></dc:creator>
		<pubDate>Thu, 09 May 2024 17:10:42 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://crbtokenhealth.com/?p=1042</guid>

					<description><![CDATA[<p>The &#8220;Cerco al Alzheimer&#8221; event, held on September 14, 2023, at the European University of Alcobendas, brought together some of the leading specialists in the field of dementia to discuss the current state of research, new therapies, and diagnostic methods in an open format. One of the key topics discussed mainly during the first two [&#8230;]</p>
<p>La entrada <a href="https://crbtokenhealth.com/en/summary-video-of-the-event-cerco-al-alzheimer/">Summary Video of the Event: &#8220;Cerco al Alzheimer&#8221;</a> se publicó primero en <a href="https://crbtokenhealth.com/en/crb-token-health-i">Crb Token Health, SL</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The &#8220;Cerco al Alzheimer&#8221; event, held on September 14, 2023, at the European University of Alcobendas, brought together some of the leading specialists in the field of dementia to discuss the current state of research, new therapies, and diagnostic methods in an open format.</p>
<p>One of the key topics discussed mainly during the first two panels of the day was the importance of assessing the risk of both rapid disease progression and the occurrence of serious side effects with new treatments in newly diagnosed patients who may receive these monoclonal antibodies.</p>
<p>These risks can be assessed through the plasma analysis of specific biomarkers in the patient, specifically Apolipoprotein E4 (APOE4), which is already available in Spain.</p>
<p><span style="color: #1db4c1;"><a style="color: #1db4c1;" href="https://vimeo.com/871373553/a7dba4ab6d?share=copy">Video Summary video panel 1</a></span><br />
<span style="color: #1db4c1;"><a style="color: #1db4c1;" href="https://vimeo.com/872869746/aaad6267fd?share=copy">Video Summary video panel 2</a></span><br />
<span style="color: #1db4c1;"><a style="color: #1db4c1;" href="https://vimeo.com/user/86927481/folder/17827741">Full Session</a></span></p>
<p><span style="color: #1db4c1;"><a style="color: #1db4c1;" href="https://crbtokenhealth.com/">Crb Token Health, SL</a></span></p>
<p>La entrada <a href="https://crbtokenhealth.com/en/summary-video-of-the-event-cerco-al-alzheimer/">Summary Video of the Event: &#8220;Cerco al Alzheimer&#8221;</a> se publicó primero en <a href="https://crbtokenhealth.com/en/crb-token-health-i">Crb Token Health, SL</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://crbtokenhealth.com/en/summary-video-of-the-event-cerco-al-alzheimer/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
